Home › Compare › MOHCF vs ABBV
MOHCF yields 7.56% · ABBV yields 3.06%● Live data
📍 MOHCF pulled ahead of the other in Year 1
Combined, MOHCF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of MOHCF + ABBV for your $10,000?
Motor Oil (Hellas) Corinth Refineries S.A. engages in oil refining and oil products trading in Greece and internationally. It operates through four segments: Refining Activity, Fuels' Marketing Activity, Power & Gas, and Other. The company produces and sells liquid fuels, lubricants, and asphalt for transportation, industrial, and household use. It also markets and distributes a range of oil products, including gasoline, fuel oil, diesel, and lubricants through a retail network of approximately 796 stations under the SHELL name; retail service comprising 24 SHELL branded fuel sites; and operates 531 gas stations under AVIN brand name and 111 gas stations under CYCLON brand. In addition, the company engages in oil trading, storage agency, and services; collection and trading of used lubricants; research, exploration, and trading of crude oil; and marketing and distribution of liquefied petroleum gas, as well as operates aircraft fuel supply system and the storage facilities at the Athens International Airport at Spata of Attica. Further, it is involved in the purchase, sale, exploitation, and development of real estate properties; and provision of liquefied petroleum gas, facilities management services, and financial services, as well as systems of alternative management of lubricant wastes. The company was founded in 1970 and is headquartered in Marousi, Greece.
Full MOHCF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.